In a study of 134 DLBCL patients, A20 deletion was found in 23.1% (31/134) of patients and 50% (14/28) in non-GBC DLBCL compared to 22.2% (4/18) in GBC DLBCL. Here, TNFAIP3 is linked to diffuse large B-cell lymphoma.